Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Fatima Ali Raza,Rafiya Altaf,Talha Bashir,Fatima Asghar,Rabiya Altaf,Sohaib Tousif,Aman Goyal,Aisha Mohammed,Mahnoor Faisal Mohammad,Mahfuza Anan,Sajjad Ali
DOI: https://doi.org/10.1097/md.0000000000040364
IF: 1.6
2024-11-06
Medicine
Abstract:Obesity is a major risk factor for cardiovascular disease (CVD) and heart failure, which contributes to higher morbidity and mortality rates worldwide. [ 1 ] Historically, weight management strategies have included a variety of approaches, including bariatric surgery and pharmacological treatments; however, these methods have frequently encountered practical limitations or side effects, making them less effective or acceptable. [ 2 ] Recent advances in pharmacotherapy have introduced GLP-1 receptor agonists (GLP-1 RAs) and gastric inhibitory polypeptide (GIP) receptor agonists, which have shown promise in both weight loss and CVD prevention. [ 3 ] These agents work by increasing insulin secretion, decreasing appetite, and improving glucose metabolism, with a growing number of GLP-1 RAs and GIP analogs now on the market, including liraglutide, semaglutide, and tirzepatide. [ 4 ] Ongoing and future trials are investigating their long-term efficacy and safety profiles, with a focus on cost, patient adherence, and side effects. [ 5 ] This review investigates the mechanism of glucagon-like peptide 1 receptor agonist (GLP-1 RA), its effects on weight loss, cardiovascular risk (CV) factors and outcomes, common adverse effects and their management, and the drugs' benefits and limitations, emphasizing the importance of careful patient selection.
medicine, general & internal